$Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia$

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia

Abstract Background Sequential CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy offers a promising approach to antigen-loss relapse in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL); however, research in adults remains limited. Methods This study aimed to evaluate...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Delin Kong, Jia Geng, Alex H. Chang, He Huang, Yongxian Hu
Format:	Article
Language:	English
Published:	BMC 2025-01-01
Series:	Experimental Hematology & Oncology
Subjects:	Relapsed/refractory B-cell acute lymphoblastic leukemia Chimeric antigen receptor Sequential therapy
Online Access:	https://doi.org/10.1186/s40164-024-00593-5
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
by: NA Batmanova, et al.
Published: (2017-07-01)

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
by: Mei Zhou, et al.
Published: (2025-07-01)

Case Report: CD19 CAR-T cells derived from recipient of umbilical cord blood transplantation effectively treated relapsed acute lymphoblastic leukemia after UCBT
by: Hua Li, et al.
Published: (2025-05-01)

Efficacy and safety of blinatumomab in Chinese patients with relapsed/refractory B-cell acute lymphoblastic leukemia: a single-center retrospective study
by: Yan Wang, et al.
Published: (2025-05-01)

Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib
by: Takayoshi Tachibana, et al.
Published: (2024-12-01)

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy
by: Lingling Yin, et al.
Published: (2025-04-01)

Extramedullary relapse of acute lymphoblastic leukemia treated with a CAR-T cell therapy bridge to unrelated cord blood transplantation: a case report and review of the literature
by: Huibo Li, et al.
Published: (2025-08-01)

CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia
by: E. V. Glukhanyuk, et al.
Published: (2019-01-01)

Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis
by: Jinhuan Xu, et al.
Published: (2025-01-01)

X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL
by: Michela Carlet, et al.
Published: (2022-11-01)

CREBBP is a Major Prognostic Biomarker for Relapse in Childhood B-cell Acute Lymphoblastic Leukemia: A National Study of Unselected Cohort
by: Krstevska Bozhinovikj E, et al.
Published: (2025-03-01)

Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL
by: Gaoxiang Wang, et al.
Published: (2025-03-01)

Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia
by: Qianyi Zhou, et al.
Published: (2025-03-01)

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy
by: Goel U, et al.
Published: (2025-02-01)

Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center
by: Ziyi Hao, et al.
Published: (2024-12-01)

Long-Term Donor Chimerism Monitoring for Relapse Risk Assessment After Pediatric Allo-HSCT
by: Prażmo A, et al.
Published: (2025-07-01)

Analysis of relapsed/refractory Hodgkin lymphoma treated with autologous transplantation: A single-center experience
by: Vishal Kulkarni, et al.
Published: (2020-01-01)

CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial
by: Jia Yin, et al.
Published: (2025-05-01)

Expression of CD123 in B-Acute Lymphoblastic Leukemia as a Predictor of BCR/ABL rearrangement and Disease Relapse
by: Birva Nimit Raiya
Published: (2025-05-01)

Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
by: Francesca Gay, et al.
Published: (2025-03-01)

Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia
by: Wenyue Cao, et al.
Published: (2025-04-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Cytogenetic and Molecular Genetic Prognostic Factors of Acute Lymphoblastic Leukemias
by: AV Misyurin
Published: (2017-07-01)

Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
by: Ya. V. Krylova, et al.
Published: (2024-09-01)

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis
by: Jing Shen, et al.
Published: (2025-08-01)

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
by: Chia Jie Tan, et al.
Published: (2025-03-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
by: Yian Zhang, et al.
Published: (2025-08-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01)

Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma
by: Xiaodan Luo, et al.
Published: (2024-12-01)

Ocular involvement in pediatric patients with acute leukemia relapse: points of diagnosis and treatment
by: G. A. Radzhabova, et al.
Published: (2025-03-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Efficiency of Inotuzumab Ozogamicin in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Relation to CD22 Expression
by: Thulasi Raman Ramalingam, et al.

Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study
by: Satoshi Yamasaki, et al.
Published: (2024-11-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data
by: Ning Lyu, et al.
Published: (2025-01-01)

Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report
by: Song-yun Wang, et al.
Published: (2024-10-01)

Updates in novel immunotherapeutic strategies for relapsed/refractory AML
by: Sawyer Bawek, et al.
Published: (2024-12-01)

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
by: Jiri Minarik, et al.
Published: (2025-04-01)